These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
303 related articles for article (PubMed ID: 30875495)
1. Statins and nonalcoholic fatty liver disease in the era of precision medicine: More friends than foes. Nascimbeni F; Pellegrini E; Lugari S; Mondelli A; Bursi S; Onfiani G; Carubbi F; Lonardo A Atherosclerosis; 2019 May; 284():66-74. PubMed ID: 30875495 [TBL] [Abstract][Full Text] [Related]
2. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870 [TBL] [Abstract][Full Text] [Related]
3. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk. Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019 [TBL] [Abstract][Full Text] [Related]
4. The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease. Doumas M; Imprialos K; Dimakopoulou A; Stavropoulos K; Binas A; Athyros VG Curr Pharm Des; 2018; 24(38):4587-4592. PubMed ID: 30652643 [TBL] [Abstract][Full Text] [Related]
5. What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis? Doumas M; Imprialos K; Stavropoulos K; Athyros VG Curr Vasc Pharmacol; 2019; 17(5):425-428. PubMed ID: 31418344 [TBL] [Abstract][Full Text] [Related]
6. Are statins 'IDEAL' for non-alcoholic fatty liver disease? Athyros VG; Katsiki N; Karagiannis A; Mikhailidis DP Curr Med Res Opin; 2014 Feb; 30(2):229-31. PubMed ID: 24127654 [TBL] [Abstract][Full Text] [Related]
8. Statins in nonalcoholic fatty liver disease and steatohepatitis: updated review. Nseir W; Mahamid M Curr Atheroscler Rep; 2013 Mar; 15(3):305. PubMed ID: 23328905 [TBL] [Abstract][Full Text] [Related]
9. Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease? Paschos P; Athyros VG; Tsimperidis A; Katsoula A; Grammatikos N; Giouleme O Curr Vasc Pharmacol; 2018; 16(3):269-275. PubMed ID: 28676018 [TBL] [Abstract][Full Text] [Related]
10. Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies. Nseir W; Mograbi J; Ghali M Dig Dis Sci; 2012 Jul; 57(7):1773-81. PubMed ID: 22419057 [TBL] [Abstract][Full Text] [Related]
11. Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease. Imprialos K; Stavropoulos K; Bouloukou S; Kerpiniotis G; Karagiannis A; Doumas M Curr Vasc Pharmacol; 2018; 16(3):276-288. PubMed ID: 28676020 [TBL] [Abstract][Full Text] [Related]
12. Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study. Thomson MJ; Serper M; Khungar V; Weiss LM; Trinh H; Firpi-Morell R; Roden M; Loomba R; Barritt AS; Gazis D; Mospan AR; Fried MW; Reddy KR; Lok AS Clin Gastroenterol Hepatol; 2022 Feb; 20(2):458-460.e4. PubMed ID: 33775894 [TBL] [Abstract][Full Text] [Related]
13. A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action. Zhang S; Ren X; Zhang B; Lan T; Liu B Molecules; 2024 Apr; 29(8):. PubMed ID: 38675679 [TBL] [Abstract][Full Text] [Related]
14. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH. Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280 [TBL] [Abstract][Full Text] [Related]
15. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Takahashi Y; Fukusato T World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438 [TBL] [Abstract][Full Text] [Related]
16. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. Loria P; Marchesini G; Nascimbeni F; Ballestri S; Maurantonio M; Carubbi F; Ratziu V; Lonardo A Atherosclerosis; 2014 Jan; 232(1):99-109. PubMed ID: 24401223 [TBL] [Abstract][Full Text] [Related]